Lataa...
Uptake of the First Biosimilar Infliximab since its Approval in South Korea
OBJECTIVE: FDA is considering an application for a biosimilar infliximab, which has been available in South Korea since November 2012. We aimed to examine the utilization patterns of both branded and biosimilar infliximab and other TNF in South Korea before and after the introduction of biosimilar i...
Tallennettuna:
| Julkaisussa: | Arthritis Rheumatol |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4848142/ https://ncbi.nlm.nih.gov/pubmed/26662931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39546 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|